Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 4NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasm Metastasis 2Hematologic Neoplasms 2Fallopian Tube Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Malignant Solid Neoplasm 1Carcinoma in Situ 1Brenner Tumor 1Breast Neoplasms 1

Interventions

Paclitaxel 27Carboplatin 23Cisplatin 16Topotecan 8Taxes 8Docetaxel 7Gemcitabine 6Filgrastim 5Etoposide 4Doxorubicin 4Cyclophosphamide 4Psychiatric Rehabilitation 3Ifosfamide 3Chemotherapy, Adjuvant 3rubitecan 2pegfilgrastim 2paclitaxel poliglumex 2liposomal doxorubicin 2Trabectedin 2Surgical Procedures, Operative 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2Irinotecan 2GEN-1 2Fenretinide 2Erlotinib Hydrochloride 2Drug Therapy 2Celecoxib 2Bevacizumab 2Amifostine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Ovarian Neoplasms × Educational Status × Clear all
NCT00958698 2019-03-12

Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

GOG Foundation

Phase NA Unknown
485 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡